miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2 | Zendy

Yan Yin | Zendy; Hua Liu | Zendy; Junhui Xu | Zendy; Dongsheng Shi | Zendy; Liang Zhai | Zendy; Bin Liu | Zendy; Lei Wang | Zendy; Guangxin Liu | Zendy; Jianwen Qin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2

Author(s) -

Yan Yin,

Hua Liu,

Junhui Xu,

Dongsheng Shi,

Liang Zhai,

Bin Liu,

Lei Wang,

Guangxin Liu,

Jianwen Qin

Publication year - 2018

Publication title -

oncology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.094

H-Index - 96

eISSN - 1791-2431

pISSN - 1021-335X

DOI - 10.3892/or.2018.6772

Subject(s) - cisplatin , oncogene , lung cancer , drug resistance , microrna , molecular medicine , cancer , cancer research , biology , cell cycle , mechanism (biology) , medicine , oncology , chemotherapy , gene , genetics , philosophy , epistemology

Chemotherapeutic drug resistance is correlated with treatment failure and poor prognosis among lung cancer patients. Numerous studies indicate the relevance of miRNAs in inducing certain drug resistance. In the course of the study, we unexpectedly found that miR‑144‑3p could regulate the cisplatin resistance of lung cancer cells via Nrf2. However, Nrf2 also could reverse activate the expression of miR‑144‑3p by binding to the ARE box in the miR‑144‑3p promoter. This may be a self‑protection mechanism of the body. In addition, we also found that in other cancer cell lines, such as HepG2, miR‑144‑3p also had the function of regulating cisplatin resistance. These findings may provide some theoretical reference for the clinical inhibition of cisplatin resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research